{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:22:03Z","timestamp":1792790523101,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Children\u2019 Cancer Foundation Project 306","id":[{"id":"https:\/\/ror.org\/009yhf078","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Children\u2019Cancer Foundation Project 306"},{"name":"Children\u2019Cancer Foundation Project 306"},{"name":"Children\u2019Cancer Foundation Project 306"},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["PdCCRS1128727"],"award-info":[{"award-number":["PdCCRS1128727"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Children\u2019Cancer Foundation Project 306"},{"name":"Children\u2019Cancer Foundation Project 306"},{"name":"Children\u2019Cancer Foundation Project 306"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Minimal residual disease (MRD) measurement is a cornerstone of contemporary acute lymphoblastic leukaemia (ALL) treatment. The presence of immunoglobulin (Ig) and T cell receptor (TCR) gene recombinations in leukaemic clones allows widespread use of patient-specific, DNA-based MRD assays. In contrast, paediatric solid tumour MRD remains experimental and has focussed on generic assays targeting tumour-specific messenger RNA, methylated DNA or microRNA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We examined the feasibility of using whole-genome sequencing (WGS) data to design tumour-specific polymerase chain reaction (PCR)-based MRD tests (WGS-MRD) in 18 children with high-risk relapsed cancer, including ALL, high-risk neuroblastoma (HR-NB) and Ewing sarcoma (EWS) (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096 each).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sensitive WGS-MRD assays were generated for each patient and allowed quantitation of 1 tumour cell per 10\n                      <jats:sup>\u22124<\/jats:sup>\n                      (0.01%)\u201310\n                      <jats:sup>\u20135<\/jats:sup>\n                      (0.001%) mononuclear cells. In ALL, WGS-MRD and Ig\/TCR-MRD were highly concordant. WGS-MRD assays also showed good concordance between quantitative PCR and droplet digital PCR formats. In serial clinical samples, WGS-MRD correlated with disease course. In solid tumours, WGS-MRD assays were more sensitive than RNA-MRD assays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>WGS facilitated the development of patient-specific MRD tests in ALL, HR-NB and EWS with potential clinical utility in monitoring treatment response. WGS data could be used to design patient-specific MRD assays in a broad range of tumours.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-021-01538-z","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T04:04:26Z","timestamp":1630469066000},"page":"482-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma"],"prefix":"10.1038","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6050-9915","authenticated-orcid":false,"given":"Vinod Vijay","family":"Subhash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libby","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Kamili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola C.","family":"Venn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6398-3046","authenticated-orcid":false,"given":"Chelsea","family":"Mayoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Venkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Tyrrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2503-0762","authenticated-orcid":false,"given":"Glenn M.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9519-5714","authenticated-orcid":false,"given":"Mark J.","family":"Cowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Ekert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0632-4589","authenticated-orcid":false,"given":"Murray D.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2741-3852","authenticated-orcid":false,"given":"Michelle J.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-9469","authenticated-orcid":false,"given":"Jamie I.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3295-228X","authenticated-orcid":false,"given":"Toby N.","family":"Trahair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"1538_CR1","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","volume":"115","author":"V Conter","year":"2010","unstructured":"Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Gr\u00fcmayer R, M\u00f6ricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206\u201314.","journal-title":"Blood"},{"key":"1538_CR2","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","volume":"118","author":"M Schrappe","year":"2011","unstructured":"Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Gr\u00fcmayer R, M\u00f6ricke A, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118:2077\u201384.","journal-title":"Blood"},{"key":"1538_CR3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","volume":"14","author":"A Vora","year":"2013","unstructured":"Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14:199\u2013209.","journal-title":"Lancet Oncol"},{"key":"1538_CR4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","volume":"15","author":"A Vora","year":"2014","unstructured":"Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014;15:809\u201318.","journal-title":"Lancet Oncol"},{"key":"1538_CR5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(15)70082-3","volume":"16","author":"CH Pui","year":"2015","unstructured":"Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol. 2015;16:465\u201374.","journal-title":"Lancet Oncol"},{"key":"1538_CR6","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","volume":"126","author":"MJ Borowitz","year":"2015","unstructured":"Borowitz MJ, Wood BL, Devidas M, Loh ML, Raetz EA, Salzer WL, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232. Blood. 2015;126:964\u201371.","journal-title":"Blood"},{"key":"1538_CR7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/archdischild-2015-309617","volume":"101","author":"J Bartram","year":"2016","unstructured":"Bartram J, Wade R, Vora A, Hancock J, Mitchell C, Kinsey S, et al. Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003. Arch Dis Child. 2016;101:449\u201354.","journal-title":"Arch Dis Child"},{"key":"1538_CR8","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","volume":"376","author":"C Parker","year":"2010","unstructured":"Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376:2009\u201317.","journal-title":"Lancet"},{"key":"1538_CR9","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","volume":"33","author":"P Bader","year":"2015","unstructured":"Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, et al. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. J Clin Oncol. 2015;33:1275\u201384.","journal-title":"J Clin Oncol"},{"key":"1538_CR10","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/leu.2013.44","volume":"27","author":"GM Marshall","year":"2013","unstructured":"Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia. 2013;27:1497\u2013503.","journal-title":"Leukemia"},{"key":"1538_CR11","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1200\/JCO.2012.48.5680","volume":"31","author":"C Eckert","year":"2013","unstructured":"Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Gr\u00fcmayer R, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol. 2013;31:2736\u201342.","journal-title":"J Clin Oncol"},{"key":"1538_CR12","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","volume":"3","author":"P Bader","year":"2019","unstructured":"Bader P, Salzmann-Manrique E, Balduzzi A, Dalle JH, Woolfrey AE, Bar M, et al. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv. 2019;3:3393\u2013405.","journal-title":"Blood Adv"},{"key":"1538_CR13","doi-asserted-by":"crossref","first-page":"e76455","DOI":"10.1371\/journal.pone.0076455","volume":"8","author":"M Karsa","year":"2013","unstructured":"Karsa M, Dalla Pozza L, Venn NC, Law T, Shi R, Giles JE, et al. Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual disease. PLoS ONE. 2013;8:e76455.","journal-title":"PLoS ONE"},{"key":"1538_CR14","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","volume":"125","author":"MA Pulsipher","year":"2015","unstructured":"Pulsipher MA, Carlson C, Langholz B, Wall DA, Schultz KR, Bunin N, et al. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood. 2015;125:3501\u20138.","journal-title":"Blood"},{"key":"1538_CR15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.13142","volume":"168","author":"R Sutton","year":"2015","unstructured":"Sutton R, Shaw PJ, Venn NC, Law T, Dissanayake A, Kilo T, et al. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br J Haematol. 2015;168:395\u2013404.","journal-title":"Br J Haematol"},{"key":"1538_CR16","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3389\/fonc.2019.00726","volume":"9","author":"I Della Starza","year":"2019","unstructured":"Della Starza I, Chiaretti S, De Propris MS, Elia L, Cavalli M, De Novi LA, et al. Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances. Front Oncol. 2019;9:726.","journal-title":"Front Oncol"},{"key":"1538_CR17","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJ van Dongen","year":"2003","unstructured":"van Dongen JJ, Langerak AW, Br\u00fcggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257\u2013317.","journal-title":"Leukemia"},{"key":"1538_CR18","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VH van der Velden","year":"2007","unstructured":"van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604\u201311.","journal-title":"Leukemia"},{"key":"1538_CR19","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","volume":"125","author":"JJ van Dongen","year":"2015","unstructured":"van Dongen JJ, van der Velden VH, Br\u00fcggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125:3996\u20134009.","journal-title":"Blood"},{"key":"1538_CR20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","volume":"129","author":"P Theunissen","year":"2017","unstructured":"Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017;129:347\u201357.","journal-title":"Blood"},{"key":"1538_CR21","doi-asserted-by":"crossref","first-page":"e27590","DOI":"10.1002\/pbc.27590","volume":"66","author":"A Schumich","year":"2019","unstructured":"Schumich A, Maurer-Granofszky M, Attarbaschi A, P\u00f6tschger U, Buldini B, Gaipa G, et al. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000. Pediatr Blood Cancer. 2019;66:e27590.","journal-title":"Pediatr Blood Cancer"},{"key":"1538_CR22","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/leu.2011.348","volume":"26","author":"NC Venn","year":"2012","unstructured":"Venn NC, van der Velden VH, de Bie M, Waanders E, Giles JE, Law T, et al. Highly sensitive MRD tests for ALL based on the IKZF1 \u03943-6 microdeletion. Leukemia. 2012;26:1414\u20136.","journal-title":"Leukemia"},{"key":"1538_CR23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fonc.2019.00455","volume":"9","author":"S Uemura","year":"2019","unstructured":"Uemura S, Ishida T, Thwin KKM, Yamamoto N, Tamura A, Kishimoto K, et al. Dynamics of minimal residual disease in neuroblastoma patients. Front Oncol. 2019;9:455.","journal-title":"Front Oncol"},{"key":"1538_CR24","doi-asserted-by":"crossref","first-page":"780129","DOI":"10.1155\/2012\/780129","volume":"2012","author":"LM Wagner","year":"2012","unstructured":"Wagner LM, Smolarek TA, Sumegi J, Marmer D. Assessment of minimal residual disease in ewing sarcoma. Sarcoma. 2012;2012:780129.","journal-title":"Sarcoma"},{"key":"1538_CR25","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0959-8049(00)00058-7","volume":"36","author":"SJ Cotterill","year":"2000","unstructured":"Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, Kohler JA, et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of the European Neuroblastoma Study Group \u2018Survey\u2019 1982-1992. Eur J Cancer. 2000;36:901\u20138.","journal-title":"Eur J Cancer"},{"key":"1538_CR26","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2014.59.4648","volume":"33","author":"NR Pinto","year":"2015","unstructured":"Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33:3008\u201317.","journal-title":"J Clin Oncol"},{"key":"1538_CR27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0002-9440(10)63669-3","volume":"163","author":"G M\u00e9hes","year":"2003","unstructured":"M\u00e9hes G, Luegmayr A, Kornm\u00fcller R, Ambros IM, Ladenstein R, Gadner H, et al. Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology. Am J Pathol. 2003;163:393\u20139.","journal-title":"Am J Pathol"},{"key":"1538_CR28","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cncr.30380","volume":"123","author":"SA Burchill","year":"2017","unstructured":"Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GA, et al. Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer. 2017;123:1095\u2013105.","journal-title":"Cancer"},{"key":"1538_CR29","doi-asserted-by":"crossref","first-page":"e28807","DOI":"10.1002\/pbc.28807","volume":"68","author":"KM Campbell","year":"2021","unstructured":"Campbell KM, Shulman DS, Grier HE, DuBois SG. Role of bone marrow biopsy for staging new patients with Ewing sarcoma: a systematic review. Pediatr Blood Cancer. 2021;68:e28807.","journal-title":"Pediatr Blood Cancer"},{"key":"1538_CR30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/JCO.2003.03.006","volume":"21","author":"G Schleiermacher","year":"2003","unstructured":"Schleiermacher G, Peter M, Oberlin O, Philip T, Rubie H, Mechinaud F, et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J Clin Oncol. 2003;21:85\u201391.","journal-title":"J Clin Oncol"},{"key":"1538_CR31","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1200\/JCO.2010.34.3392","volume":"29","author":"WB London","year":"2011","unstructured":"London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011;29:3286\u201392.","journal-title":"J Clin Oncol"},{"key":"1538_CR32","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2005.05.105","volume":"23","author":"LM Barker","year":"2005","unstructured":"Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing\u2019s sarcoma family of tumors. J Clin Oncol. 2005;23:4354\u201362.","journal-title":"J Clin Oncol"},{"key":"1538_CR33","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1373\/clinchem.2008.117945","volume":"55","author":"J Stutterheim","year":"2009","unstructured":"Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, et al. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clin Chem. 2009;55:1316\u201326.","journal-title":"Clin Chem"},{"key":"1538_CR34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejca.2006.08.007","volume":"43","author":"VF Viprey","year":"2007","unstructured":"Viprey VF, Corrias MV, Kagedal B, Oltra S, Swerts K, Vicha A, et al. Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET. Eur J Cancer. 2007;43:341\u201350.","journal-title":"Eur J Cancer"},{"key":"1538_CR35","doi-asserted-by":"publisher","unstructured":"Chaput L, Gr\u00e8ze V, Halle P, Radosevic-Robin N, Pereira B, V\u00e9ron\u00e8se L, et al. Sensitive and specific detection of Ewing sarcoma minimal residual disease in ovarian and testicular tissues in an in vitro model. Cancers. 2019;11:1807. https:\/\/doi.org\/10.3390\/cancers11111807.","DOI":"10.3390\/cancers11111807"},{"key":"1538_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/modpathol.3800486","volume":"19","author":"RS Bridge","year":"2006","unstructured":"Bridge RS, Rajaram V, Dehner LP, Pfeifer JD, Perry A. Molecular diagnosis of Ewing sarcoma\/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors. Mod Pathol. 2006;19:1\u20138.","journal-title":"Mod Pathol"},{"key":"1538_CR37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jmoldx.2011.12.002","volume":"14","author":"J Stutterheim","year":"2012","unstructured":"Stutterheim J, Zappeij-Kannegieter L, Ora I, van Sluis PG, Bras J, den Ouden E, et al. Stability of PCR targets for monitoring minimal residual disease in neuroblastoma. J Mol Diagn. 2012;14:168\u201375.","journal-title":"J Mol Diagn"},{"key":"1538_CR38","doi-asserted-by":"publisher","unstructured":"van Zogchel LMJ, van Wezel EM, van Wijk J, Stutterheim J, Bruins WSC, Zappeij-Kannegieter L, et al. Hypermethylated RASSF1A as circulating tumor DNA marker for disease monitoring in neuroblastoma. JCO Precis Oncol. 2020;4:PO.19.00261. https:\/\/doi.org\/10.1200\/PO.19.00261.","DOI":"10.1200\/PO.19.00261"},{"key":"1538_CR39","doi-asserted-by":"publisher","unstructured":"Morini M, Cangelosi D, Segalerba D, Marimpietri D, Raggi F, Castellano A, et al. Exosomal microRNAs from longitudinal liquid biopsies for the prediction of response to induction chemotherapy in high-risk neuroblastoma patients: a proof of concept SIOPEN study. Cancers. 2019;11:1476. https:\/\/doi.org\/10.3390\/cancers11101476.","DOI":"10.3390\/cancers11101476"},{"key":"1538_CR40","doi-asserted-by":"publisher","unstructured":"Peitz C, Spr\u00fcssel A, Linke RB, Astrahantseff K, Grimaldi M, Schmelz K, et al. Multiplexed quantification of four neuroblastoma DNA targets in a single droplet digital PCR reaction. J Mol Diagn. 2020. https:\/\/doi.org\/10.1016\/j.jmoldx.2020.07.006.","DOI":"10.1016\/j.jmoldx.2020.07.006"},{"key":"1538_CR41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23445-w","volume":"12","author":"P Peneder","year":"2021","unstructured":"Peneder P, St\u00fctz AM, Surdez D, Krumbholz M, Semper S, Chicard M, et al. Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. Nat Commun. 2021;12:3230.","journal-title":"Nat Commun"},{"key":"1538_CR42","doi-asserted-by":"publisher","unstructured":"van Zogchel LMJ, Zappeij-Kannegieter L, Javadi A, Lugtigheid M, Gelineau NU, Lak NSM, et al. Specific and sensitive detection of neuroblastoma mRNA markers by multiplex RT-qPCR. Cancers. 2021;13:150. https:\/\/doi.org\/10.3390\/cancers13010150.","DOI":"10.3390\/cancers13010150"},{"key":"1538_CR43","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1200\/JCO.2013.53.3604","volume":"32","author":"VF Viprey","year":"2014","unstructured":"Viprey VF, Gregory WM, Corrias MV, Tchirkov A, Swerts K, Vicha A, et al. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1\/SIOPEN study. J Clin Oncol. 2014;32:1074\u201383.","journal-title":"J Clin Oncol"},{"key":"1538_CR44","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","volume":"33","author":"N Gaspar","year":"2015","unstructured":"Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33:3036\u201346.","journal-title":"J Clin Oncol"},{"key":"1538_CR45","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41591-020-1072-4","volume":"26","author":"M Wong","year":"2020","unstructured":"Wong M, Mayoh C, Lau LMS, Khuong-Quang DA, Pinese M, Kumar A, et al. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med. 2020;26:1742\u201353.","journal-title":"Nat Med"},{"key":"1538_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0682-4","author":"A Kamili","year":"2020","unstructured":"Kamili A, Gifford AJ, Li N, Mayoh C, Chow SO, Failes TW, et al. Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy. Br J Cancer. 2020. https:\/\/doi.org\/10.1038\/s41416-019-0682-4.","journal-title":"Br J Cancer"},{"key":"1538_CR47","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/bloodadvances.2020003738","volume":"5","author":"CH Tsai","year":"2021","unstructured":"Tsai CH, Tang JL, Tien FM, Kuo YY, Wu DC, Lin CC, et al. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Adv. 2021;5:2456\u201366.","journal-title":"Blood Adv"},{"key":"1538_CR48","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","volume":"132","author":"T Kim","year":"2018","unstructured":"Kim T, Moon JH, Ahn JS, Kim YK, Lee SS, Ahn SY, et al. Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. Blood. 2018;132:1604\u201313.","journal-title":"Blood"},{"key":"1538_CR49","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","volume":"28","author":"M Ladetto","year":"2014","unstructured":"Ladetto M, Br\u00fcggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28:1299\u2013307.","journal-title":"Leukemia"},{"key":"1538_CR50","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1038\/sj.onc.1207717","volume":"23","author":"CA Stiller","year":"2004","unstructured":"Stiller CA. Epidemiology and genetics of childhood cancer. Oncogene. 2004;23:6429\u201344.","journal-title":"Oncogene"},{"key":"1538_CR51","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546\u201358.","journal-title":"Science"},{"key":"1538_CR52","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/sj.leu.2404535","volume":"21","author":"VH van der Velden","year":"2007","unstructured":"van der Velden VH, Panzer-Gr\u00fcmayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia. 2007;21:706\u201313.","journal-title":"Leukemia"},{"key":"1538_CR53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/path.2406","volume":"216","author":"VF Viprey","year":"2008","unstructured":"Viprey VF, Lastowska MA, Corrias MV, Swerts K, Jackson MS, Burchill SA. Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. J Pathol. 2008;216:245\u201352.","journal-title":"J Pathol"},{"key":"1538_CR54","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1158\/1078-0432.CCR-11-0849","volume":"18","author":"J Stutterheim","year":"2012","unstructured":"Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GA, et al. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma. Clin Cancer Res. 2012;18:808\u201314.","journal-title":"Clin Cancer Res"},{"key":"1538_CR55","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/bjh.15056","volume":"180","author":"R Sutton","year":"2018","unstructured":"Sutton R, Venn NC, Law T, Boer JM, Trahair TN, Ng A, et al. A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children. Br J Haematol. 2018;180:550\u201362.","journal-title":"Br J Haematol"},{"key":"1538_CR56","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/bloodadvances.2017009845","volume":"1","author":"M Br\u00fcggemann","year":"2017","unstructured":"Br\u00fcggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv. 2017;1:2456\u201366.","journal-title":"Blood Adv"},{"key":"1538_CR57","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-12-4081","volume":"73","author":"X Zhang","year":"2013","unstructured":"Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013;73:4885\u201397.","journal-title":"Cancer Res"},{"key":"1538_CR58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jmoldx.2014.09.005","volume":"17","author":"EM van Wezel","year":"2015","unstructured":"van Wezel EM, Zwijnenburg D, Zappeij-Kannegieter L, Bus E, van Noesel MM, Molenaar JJ, et al. Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma. J Mol Diagn. 2015;17:43\u201352.","journal-title":"J Mol Diagn"},{"key":"1538_CR59","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jmoldx.2019.10.012","volume":"22","author":"KKM Thwin","year":"2020","unstructured":"Thwin KKM, Ishida T, Uemura S, Yamamoto N, Lin KS, Tamura A, et al. Level of seven neuroblastoma-associated mRNAs detected by droplet digital PCR is associated with tumor relapse\/regrowth of high-risk neuroblastoma patients. J Mol Diagn. 2020;22:236\u201346.","journal-title":"J Mol Diagn"},{"key":"1538_CR60","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1158\/1078-0432.CCR-16-2082","volume":"23","author":"MR Abbasi","year":"2017","unstructured":"Abbasi MR, Rifatbegovic F, Brunner C, Mann G, Ziegler A, P\u00f6tschger U, et al. Impact of disseminated neuroblastoma cells on the identification of the relapse-seeding clone. Clin Cancer Res. 2017;23:4224\u201332.","journal-title":"Clin Cancer Res"},{"key":"1538_CR61","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1158\/1078-0432.CCR-17-1586","volume":"24","author":"M Chicard","year":"2018","unstructured":"Chicard M, Colmet-Daage L, Clement N, Danzon A, Bohec M, Bernard V, et al. Whole-exome sequencing of cell-free DNA reveals temporo-spatial heterogeneity and identifies treatment-resistant clones in neuroblastoma. Clin Cancer Res. 2018;24:939\u201349.","journal-title":"Clin Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01538-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01538-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01538-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T05:03:46Z","timestamp":1643778226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01538-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2,1]]}},"alternative-id":["1538"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01538-z","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"22 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All tumour specimens were obtained under approval by the SCHN Human Research Ethics Committee (LNR\/14\/SCHN\/497) or Hunter New England Human Research Ethics Committee (HREC\/17\/HNE\/29). Informed parental or guardian consent was obtained for each patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All samples used in this study were de-identified. No personal information was exposed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}